View More 2023, Planning Resources, Scientific Sessions

Scientific Sessions features four days of cutting-edge basic, translational, and clinical science


Estimated Read Time:

3 minutes

Alice Y.Y. Cheng, MD, FRCPC
Alice Y.Y. Cheng, MD, FRCPC

Final preparations are underway for the 83rd Scientific Sessions of the American Diabetes Association® (ADA) in San Diego, June 23-26, where researchers and health care professionals from around the world will gather to share ideas and learn about the most significant advances and breakthroughs in diabetes.

The Scientific Sessions Meeting Planning Committee has assembled a robust program featuring more than 190 sessions and 2,000 original research presentations covering the hottest topics, trials, and trends in diabetes research, prevention, and care. Complementing the top-notch science, the committee has introduced some format changes and new offerings designed to enhance the learning experience, according to Scientific Sessions Meeting Planning Committee Chair Alice Y.Y. Cheng, MD, FRCPC.

“We’ve consolidated the meeting from five days to four, but within that timeframe we’re going to have a lot more debates, more panel discussions, more meet-the-expert sessions, all designed to increase interaction with the speakers and make sessions more engaging for the audience,” Dr. Cheng said.

The program is categorized into eight distinct themes, allowing attendees to focus on their specialty or expand their knowledge in other areas. View the Advance Program.

Scientific Sessions Theme Areas

  • Acute and Chronic Complications
  • Behavioral Medicine, Clinical Nutrition, Education, and Exercise
  • Clinical Diabetes/Therapeutics
  • Epidemiology/Genetics
  • Immunology/Beta-Cell Replacement
  • Insulin Action/Molecular Metabolism
  • Obesity/Integrated Physiology
  • Islet Biology/Insulin Secretion

As always, the Scientific Sessions will also feature the latest clinical trial findings, the most highly anticipated study results, and the most impactful emerging breakthroughs in basic science.

“We’ll hear all of the latest-breaking results from studies across the spectrum of diabetes research, including some exciting new findings from trials looking at novel therapies for treating obesity in type 2 diabetes,” Dr. Cheng said. “We also have many great sessions and abstract presentations that highlight breakthroughs and hot topics in type 1 diabetes, including the promise of immunotherapy and important new findings related to automated insulin delivery during pregnancy in type 1 diabetes.”

The following sessions feature major trial results that will be presented at the 83rd Scientific Sessions. Stay tuned to the ADA Meeting News for more information about the latest-breaking research that will be presented in San Diego.

  • SURMOUNT 2 Trial Results and Potential Role of Tirzepatide in Treating Obesity in Type 2 Diabetes
  • COORDINATE—Diabetes Study Results Symposium
  • Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon Receptor Triagonist—Obesity, NAFLD, and T2D Phase 2 Trial Results
  • Is Metabolic Surgery or Lifestyle/Medical Management of Type 2 Diabetes Optimal for Long-Term Health? Long-Term Outcomes of the ARMMS-T2D Randomized Trial after 7–15 Years of Follow-Up
  • Oral Semaglutide for Treatment of Obesity and Type 2 Diabetes—Results from OASIS 1 and PIONEER PLUS Trials
  • The New Normal—Perspectives on Treatment and Trials as Immunotherapies Enter the Type 1 Diabetes Clinical Landscape
  • Bempedoic Acid and Cardiovascular Outcomes in Statin-Intolerant Patients—CLEAR-Outcomes trial

Registration for the 83rd Scientific Sessions should be completed via the ADA’s secure online registration portal, which features special pricing for three categories of attendees: ADA members, non-members, and students/residents/fellows.